Vigil Neuroscience, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.

Vigil Neuroscience, Inc. (formerly Nasdaq: VIGL) generated news as a clinical-stage biotechnology company focused on microglia and TREM2-targeted therapies for neurodegenerative diseases. Company announcements highlighted progress across its two main programs: iluzanebart, a fully human monoclonal antibody TREM2 agonist for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), and VG-3927, a novel orally bioavailable small molecule TREM2 agonist for common neurodegenerative diseases, initially Alzheimer’s disease.

News coverage for Vigil included clinical trial updates, such as data from the Phase 2 IGNITE trial of iluzanebart in ALSP and Phase 1 trial results for VG-3927, which assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, elderly participants, and Alzheimer’s disease patients. The company also reported on its ILLUMINATE natural history study in ALSP, which was designed to improve understanding of disease progression and biomarkers.

Corporate and strategic developments were another major source of news. Vigil disclosed a strategic investment from Sanofi tied to its small molecule TREM2 agonist program and later announced a definitive merger agreement under which Sanofi would acquire Vigil. Subsequent news detailed shareholder approval, litigation-related disclosure supplements, and the completion of the acquisition, after which Vigil became a wholly owned subsidiary of Sanofi.

This news archive allows readers to follow Vigil Neuroscience’s historical clinical milestones, scientific presentations at neurology-focused conferences, financing and strategic transactions, and the regulatory steps that led to its delisting and deregistration as an independent public company.